PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling

Abstract

Oral squamous cell carcinoma (OSCC) has a high incidence of metastasis. Tumour immunotherapy targeting PD-L1 or PD-1 has been revolutionary; however, only a few patients with OSCC respond to this treatment. Therefore, it is essential to gain insights into the molecular mechanisms underlying the growth and metastasis of OSCC. In this study, we analysed the expression levels of protein kinase D3 (PKD3) and PD-L1 and their correlation with the expression of mesenchymal and epithelial markers. We found that the expression of PKD3 and PD-L1 in OSCC cells and tissues was significantly increased, which correlated positively with that of mesenchymal markers but negatively with that of epithelial markers. Silencing PKD3 significantly inhibited the growth, metastasis and invasion of OSCC cells, while its overexpression promoted these processes. Our further analyses revealed that there was positive feedback regulation between PKD3 and PD-L1, which could drive EMT of OSCC cells via the ERK/STAT1/3 pathway, thereby promoting tumour growth and metastasis. Furthermore, silencing PKD3 significantly inhibited the expression of PD-L1, and lymph node metastasis of OSCC was investigated with a mouse footpad xenograft model. Thus, our findings provide a theoretical basis for targeting PKD3 as an alternative method to block EMT for regulating PD-L1 expression and inhibiting OSCC growth and metastasis.

References

[1] Torre LA, . Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65: 87-108.

[2] Sathiyasekar AC, . Overview of immunology of oral squamous cell carcinoma. J. Pharm. Bioallied Sci., 2016, 8: S8.

[3] Carreras-Torras C, Gay-Escoda C. Techniques for early diagnosis of oral squamous cell carcinoma: systematic review. Med. Oral Patol. Oral Cir. Bucal, 2015, 20

[4] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science, 2011, 331: 1559-1564.

[5] Heerboth S, . EMT and tumor metastasis. Clin. Transl. Med., 2015, 4: 6.

[6] Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2: 442-454.

[7] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol., 2014, 15: 178.

[8] Cano A, . The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol., 2000, 2: 76-83.

[9] Roy A, Ye J, Deng F, Wang QJ. Protein kinase D signaling in cancer: a friend or foe?. Biochim. Biophys. Acta, 2017, 1868: 283-294.

[10] Durand N, Borges S, Storz P. Protein kinase D enzymes as regulators of EMT and cancer cell invasion. J. Clin. Med., 2016, 5: 20.

[11] Chen J, . Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology, 2012, 217: 385-393.

[12] Zou Z, . PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB-and HDAC1-mediated expression and activation of uPA. J. Cell Sci., 2012, 125: 4800-4811.

[13] Chen J, Deng F, Singh SV, Wang QJ. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCε/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res., 2008, 68: 3844-3853.

[14] Cui B, . Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling. Int. J. Oncol., 2020, 56: 909-920.

[15] Huck B, Duss S, Hausser A, Olayioye MA. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J. Biol. Chem., 2014, 289: 3138-3147.

[16] Borges S, . Effective targeting of estrogen receptor–negative breast cancers with the protein kinase D inhibitor CRT0066101. Mol. Cancer Ther., 2015, 14: 1306-1316.

[17] Baker J, . Protein kinase D3 modulates MMP1 and MMP13 expression in human chondrocytes. PLoS ONE, 2018, 13

[18] Wang K, . FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene, 2018, 37: 5340-5354.

[19] Khan S, . Centchroman suppresses breast cancer metastasis by reversing epithelial–mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling. Int. J. Biochem. Cell Biol., 2015, 58: 1-16.

[20] Feng, Z. M., & Guo, S. M. Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-kappaB pathway and epithelial-mesenchymal transition. Genet. Mol. Res. 15, gmr7844 (2016).

[21] Sun Y, . Inhibition of STAT signalling in bladder cancer by diindolylmethane-relevance to cell adhesion, migration and proliferation. Curr. Cancer Drug Targets, 2013, 13: 57-68.

[22] Cui Y, . STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer. Oncol. Rep., 2016, 36: 108-116.

[23] Alsuliman A, . Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol. Cancer, 2015, 14

[24] Ritprajak P, Azuma MJOo. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral. Oncol., 2015, 51: 221-228.

[25] Ock C-Y, . PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 2016, 7: 15901.

[26] Dong H, . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 2002, 8: 793.

[27] Guarino M, Rubino B, Ballabio G. The role of epithelial‐mesenchymal transition in cancer pathology. Pathology, 2007, 39: 305-318.

[28] Chen L, . Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat. Commun., 2014, 5: 1-12.

[29] Noman MZ, . The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. OncoImmunology, 2017, 6

[30] Kim S, . PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum. Pathol., 2016, 58: 7-14.

[31] Chen L, . PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer. Cell. Physiol. Biochem., 2017, 42: 2267-2280.

[32] Qiu XY, . PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim. Biophys. Acta Mol. Basis Dis., 2018, 1864: 1754-1769.

[33] Yasutoshi A, . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 1996, 8: 765-772.

[34] Benson DM Jr, . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 2010, 116: 2286-2294.

[35] Karyampudi L, . PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Cancer Res., 2016, 76: 239-250.

[36] Gordon SR, . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 2017, 7655: 495-499.

[37] Lee Y, . CD44+ cells in head and neck squamous cell carcinoma suppress T-cell–mediated immunity by selective constitutive and inducible expression of PD-L1. Clin. Cancer Res., 2016, 22: 3571-3581.

[38] Vassilakopoulou M, . Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin. Cancer Res., 2016, 22: 704-713.

[39] Rey O, Yuan J, Young SH, Rozengurt E. Protein kinase Cν/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. J. Biol. Chem., 2003, 278: 23773-23785.

[40] Wetzker R, Böhmer FD. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol., 2003, 4: 651-657.

[41] Burger M, Hartmann T, Burger JA, Schraufstatter IJO. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene, 2005, 24: 2067-2075.

[42] Wang Y, . IKK epsilon kinase is crucial for viral G protein-coupled receptor tumorigenesis. Proc. Natl Acad. Sci. USA, 2013, 110: 11139-11144.

[43] BUGGY JosephJ. Binding of α-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochem. J., 1998, 331: 211-216.

[44] Chen RJ, . Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol. Sci., 2008, 104: 283-293.

[45] Plaza-Menacho I, . Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. J. Biol. Chem., 2007, 282: 6415-6424.

[46] Sun Q, . PDGF-BB induces PRMT1 expression through ERK1/2 dependent STAT1 activation and regulates remodeling in primary human lung fibroblasts. Cell Signal., 2016, 28: 307-315.

[47] Cho HJ, . IFN‐γ‐induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia, 2007, 55: 253-262.

[48] Gough DJ, Koetz L, Levy DE. The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation. PLoS ONE, 2013, 8

[49] Gkouveris Ioannis, . Erk1/2 activation and modulation of STAT3 signaling in oral cancer. Oncol. Rep., 2014, 32: 2175-2182.

[50] Fang Y, . MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS ONE, 2013, 8

[51] Qiu W, . Phos-tag SDS-PAGE resolves agonist- and isoform-specific activation patterns for PKD2 and PKD3 in cardiomyocytes and cardiac fibroblasts. J. Mol. Cell. Cardiol., 2016, 99: 14-22.

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81802717, 81372892)